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Purpose. To describe and correlate the degree of anterior segment inflammation with central retinal and choroidal thickness throughout
the treatment period (in the course of follow-up) in the eyes affected with acute anterior uveitis in the patients with seronegative
spondyloarthropathy (subgroup: ankylosing spondylitis). Methods. )irty eyes of 30 consecutive Caucasian patients with HLA-B27-
associated acute anterior uveitis were included in this study. )e flare, AC cell number, and central retinal/choroidal thickness were
determined at each visit by optical coherence tomography and laser flare photometry. Treatment consisted of topical corticosteroids.
Statistical analysis was performed byMathWorksMatlab software. Results. In the follow-up period, central retinal thickness was increased
in the first 9-10 days and then decreased until stabilization (after 5-6 weeks). )e flare and AC cell number decreased rapidly at the
beginning of the treatment, in the first 10 days, and thereafter, slower decrease could be observed until complete resolution of in-
flammation. Statistically significant, positive correlation was found between initial laser flare value and maximal central retinal thickness
(r � 0.881, p< 0.001). Positive correlation between flare and retinal thickening was observable throughout the treatment period. Central
choroidal thickness was decreased also significantly during the follow-up (p< 0.001). Conclusions. )e retina and choroid may play
a biomarker function in the anterior segment inflammation of the eye in the patients with seronegative spondyloarthropathy.
1. Introduction
Spondyloarthropathy (SpA) is a group of chronic in-
flammatory rheumatic diseases, which are characterized by
common clinical symptoms and genetic similarities [1].
Spondyloarthropathy is genetically linked (90% of cases), and
the strongest contributing factor is the HLA B27 antigen [1, 2].
Ocular inflammation is a common extra-articular manifesta-
tion of seronegative spondyloarthropathy. Anterior uveitis is
one of the most important features with a prevalence of 25–
30% in the SpA patients [1, 2]. Five major subtypes of SpA are
recognized on the basis of recently proposed classification
criteria (European Spondyloarthropathy Study Group). In this
study, one of the most common subtypes of SpA ankylosing
spondylitis (AS) was studied intentionally.
Acute inflammatory process in the anterior segment, as
opposed to chronic anterior uveitis, is rarely associated with
significant macular edema, but subclinical retinal thickening
has already been described [3, 4]. Our earlier results showed
also close linear correlation between central foveal thickness
and anterior segment inflammation (laser flare photometry
values) at the beginning of the first anterior uveitic attack in
the patients with HLA-B27-related spondyloarthropathy [3].
In recent years, some studies have used EDI-OCT to
evaluate choroidal changes in ocular inflammatory disorders
[5, 6]. Some authors have reported that the patients with
active Vogt–Koyanagi–Harada disease [5] and Behçet dis-
ease [6] exhibit a markedly thickened choroid. Currently,
there are a limited number of reports on choroidal thickness
change in anterior uveitis [7].
)e aim of this study was to describe the evolution of
retinal and choroidal thickness in eyes affected with acute
anterior uveitis in the course of follow-up in the patients with
seronegative spondyloarthropathy. Our goal was to evaluate
Hindawi
Journal of Ophthalmology
Volume 2018, Article ID 9136017, 6 pages
https://doi.org/10.1155/2018/9136017
the correlation between flare and retinal/choroidal thickening
throughout the treatment period.
2. Materials and Methods
)is prospective study was performed at the Department of
Ophthalmology of the Semmelweis University (Budapest,
Hungary) on 30 eyes of 30 consecutive Caucasian patients
(24 males and 6 females; age: 27–50 years; mean age: 35
years) with acute anterior uveitis for the first time.
Before their first uveitic attack, rheumatic diseases, se-
ronegative spondyloarthropathy (subtype: ankylosing
spondylitis), have been diagnosed by rheumatologist. All
patients were HLA-B27 positive. )e patients with a history
of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis
associated with inflammatory bowel disease (AIBD), other
systemic diseases, intermediate uveitis, posterior uveitis,
intraocular surgery, macular disease (e.g., epiretinal fibrosis
and diabetic maculopathy), and amblyopic eyes were ex-
cluded from the study. Ankylosing Spondylitis Disease
Activity Score (ASDAS) of the patients in this study was less
than 2.0 to define “moderate disease activity.” All of them
were treated with systemic nonsteroidal anti-inflammatory
drugs by rheumatologist.
All participants were treated in accordance with the
tenets of the Declaration of Helsinki. Written informed
consent was obtained from all participants in this study.
All patients underwent a comprehensive eye examina-
tion, including best corrected visual acuity (BCVA), mea-
surement of the intraocular pressure, and slit-lamp and
indirect fundus examination after pupil dilation. )e axial
length (AL) of the eyes was measured using optical biometry
(Lenstar LS 900 Haag-Streit AG, Switzerland).
OCT examinations were performed on each eye using
EDI-OCT (Optovue Inc., Fremont, CA, USA) and swept-
source optical coherence tomograph (DRI OCT Triton,
Topcon Co., Tokyo, Japan) by the same operator through
dilated pupils at least 5mm in diameter. )e retinal and
choroidal thickness measurements for the central ETDRS
region of the macula were recorded at each visit throughout
the treatment period (Figure 1).
Quantitative measurements of anterior segment aqueous
flare and inflammatory cells were conducted using a laser
flare meter (Kowa FC-600). Flare values and cell counts were
measured at 30 minutes after pupillary dilation. )e same
examiner has obtained five measurements from each eye,
and the results were averaged after excluding all measure-
ments with artefacts.
SUN (Standardization of Uveitis Nomenclature)Working
Group standardized the grading of anterior segment cells and
flare. For anterior segment cells, in a field size of 1× 1mm slit
beam, the following grades were described: 0 (<1 cell), 0.5+
(1–5 cells), 1+ (6–15 cells), 2+ (16–25 cells), 3+ (26–50 cells),
and 4+ (>50 cells). )e number of the anterior segment cells
was also determined, counted using SUN criteria.
All uveitic eyes were initially managed with topical
corticosteroid drops (prednisolone acetate 1%) every 1–6
hours depending on severity and cyclopentolate (5mg/ml)
three times a day. Steroid was withdrawn slowly, and cor-
ticosteroid drops were continued until the cellular reaction is
absent. Cycloplegics were discontinued when the cellular
reaction is subsiding. )e patients were followed daily until
manifest response to local treatment was observed (defined
as a decrease of anterior segment cells on slit-lamp exam-
ination or a decrease of more than 20% from the baseline in
laser flare photometry) and weekly thereafter until complete
resolution of inflammatory activity.
Statistical analysis was performed byMathWorksMatlab
2012b software and its Statistics Toolbox. A p value of less
than 0.05 was considered as statistically significant.
3. Results
)e clinical signs data at the beginning of the first in-
flammatory episode (best corrected visual acuity (BCVA),
flare, anterior segment cells (AC), intraocular pressure,
central retinal thickness, and central choroidal thickness) are
shown in Table 1.
As expected, flare and anterior segment cell number are
significantly lower between initial flare/AC cell number and
final flare/AC cell number (p< 0.001).
Figure 2 presents the evolution of the mean laser flare
value in the course of follow-up. AC cell number in
the anterior uveitic eyes is significantly decreased during the
treatment period (p< 0.001), as shown in Figure 3. )e
mean initial laser flare value is reduced by 50% after 12 days.
Flare and AC cell number are decreased rapidly at the be-
ginning of the treatment, in the first 10 days, and thereafter
decreased slowly until complete resolution of inflammation.
)e central retinal thickness was significantly decreased
(p< 0.001) between the beginning and the end of the follow-
up period. Figure 4 shows the evolution of mean central
retinal thickness in the treatment period. In the follow-up
period, central retinal thickness increased a little in the first
9-10 days, followed by a progressive decrease until stabili-
zation (after 5-6 weeks). )e mean difference between the
initial and maximal retinal thickness was 8.367 µm.
Statistically significant, positive correlation was found
between initial laser flare value and maximal central retinal
thickness (r � 0.881, p< 0.001) in this homogenous group of
uveitic eyes, as shown in Figure 5. Figure 6 demonstrates that
the positive correlation between flare and retinal thickness
remained throughout the treatment period.
Finally, the central (subfoveal) choroidal thickness was
significantly decreased (p< 0.001) in the treatment period,
as shown in Figures 7 and 8.
4. Discussion
Our study demonstrated a pattern of evolution of the retinal and
choroidal thickness and flare values throughout the treatment
period in the eyes affected by HLA-B27-associated acute an-
terior uveitis (AAU) (subgroup: ankylosing spondylitis).
)e most common posterior segment findings in AAU are
subclinical increase in retinal thickness, choroidal thickness,
and macular edema. A number of studies have investigated
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Figure 1: Retinal (a) and choroidal (b) thickness measurements by swept-source optical coherence tomograph (DRI OCT Triton, Topcon
Co., Tokyo, Japan).
Table 1: Clinical signs of the first anterior uveitic attack in ankylosing spondylitis patients.
BCVA
(Snellen)
Flare
(photon/unit)
AC cell
number (SUN)
IOP
(Hgmm)
Central retinal
thickness (µm)
Central choroidal
thickness (µm)
Minimum 0.6 66.63 12 11 189.00 245.00
Maximum 1.0 135.23 35 18 262.00 312.00
Mean 0.90 90.52 15.56 14.24 220.171 278.166
Standard deviation 0.120 25.315 7.695 2.450 21.056 21.475
Median 0.9 90.23 16 14 219.3 275.5
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Figure 2: )e evolution of the mean laser flare value in the course of follow-up of the acute anterior uveitic patient with ankylosing
spondylitis. )e mean initial laser flare value is reduced by 50% after 12 days.
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retinal thickness of the anterior uveitic patients at the onset of
the inflammation [3, 4, 8–10]. For instance, Moreno-Arrones
et al. [4], Balaskas et al. [8], and our earlier study [3] also
described statistically significant difference in retinal thickness
between the uveitic eyes and the fellow eyes for all OCT
subfields. In contrast, de Lahitte et al. described only peri-
foveolar, pericentral thickening in the patients with juvenile
idiopathic arthritis-associated chronic anterior uveitis [11].
Our earlier results have shown that changes of the an-
terior segment inflammation might cause subclinical retinal
changes [3]. We suppose that ocular inflammation may
produce a breakdown of the blood-retinal barrier and in-
crease vascular permeability which generates retinal
thickening.
In our current study, the evolution of the mean central
foveal thickness and anterior segment flare values in the
treatment period was shown. In this follow-up period,
central retinal thickness increased a little in the first 10 days,
followed by a progressive decrease until stabilization (after
5-6 weeks). )e mean difference between the initial and
maximal retinal thickness was 8.367 µm in our study. )e
maximal retinal thickness of the affected eyes was observed
on day 9-10 from the beginning of the inflammation.
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Figure 5: Statistically significant, positive correlation was found
between initial laser flare value and maximal central retinal
thickness (r � 0.881, p< 0.001) in the acute anterior uveitic eyes.
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Figure 3: )e evolution of AC cell number (SUN) during the
treatment period of the acute anterior uveitic patient with anky-
losing spondylitis.
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Figure 4: )e evolution of mean central retinal thickness in the
treatment period of the acute anterior uveitic patient with anky-
losing spondylitis (the mean central retinal thickness value is
represented by a bold line).
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Figure 6: Positive linear correlation between flare and retinal
thickness remained throughout the treatment period: (a) 0 days; (b)
10 days; (c) 30 days.
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)is time lag between the retinal thickening and the
onset of inflammation may be the explanation of the de-
velopment of Irvine–Gass syndrome, whereas macular
edema presents several weeks following cataract surgery
(inflammatory agents). )e other typical phenomenon is
diabetic macular edema, which develops slowly as an ac-
cumulative response of the retina for multiple factors, that is,
inflammation. )e main factor triggering macular edema is
the release of inflammatorymediators. In chronic uveitis, the
repeated/long-lasting inflammatory stimuli could result in
additive effects on the retinal thickening. In alignment,
Balaskas et al. presented also an increase in retinal thickness
over a period of 17 to 25 days in the AAU patients [8]. An
important result is that retinal thickness, as measured by
OCT, is a useful clinical parameter to monitor response to
treatment. Changes in retinal thickness in the AAU patients
demonstrate the characteristic pattern of the retinal response
to inflammation and therapy. )e reply of the retina for the
inflammatory agents seems to be delayed.
Anterior segment cells were counted using SUN criteria,
but we have used also laser flare photometry (LFP) to
eliminate the subjectivity in measurements of anterior
segment cells by slit-lamp biomicroscopy [12, 13]. LFP re-
sults were always interpreted in conjunction with the clinical
observations. Flare and AC cell number were decreased
rapidly at the beginning of the treatment, in the first 10 days,
and thereafter, slower decrease could be observed until
complete resolution of inflammation. While the in-
flammation values decreased rapidly in the first 10 days, the
retinal thickness increased slightly in this period; however,
after 10 days, both parameters decreased during the follow-
up period.
)e mean initial laser flare value was reduced by 50%
after 12 days in our study. In the literature, Balaskas et al. [8]
described a 50% reduction of flare after 14 days, and de
Ancos et al. [14] observed the same drop after 2 days.
Contradictory results may come from a different initial
severity of the anterior segment inflammation in the studies.
According to our results, retinal thickness increased slightly
in the first 10 days when flare reduction was remarkable;
however, significant changes in retinal thickness values
could be observed later in the treatment period.
As shown in our earlier study, positive correlation was
found between initial central foveal thickness and initial
laser flare values of the uveitic patient with HLA-B27-
related spondyloarthropathy [3]. Gonzales et al. also de-
scribed that flare was significantly higher in the uveitic
patients with macular edema than in patients without
macular edema [12].
In this study, positive correlation was demonstrated
between flare and central retinal thickness throughout the
treatment period, and also, close correlation was shown
between initial laser flare values and maximal central retinal
thickness. Accordingly, the retina may be an indicator not
only of posterior segment inflammation activity but also the
anterior segment inflammation.
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Figure 7: )e evolution of mean central (subfoveal) choroidal
thickness in the treatment period of the acute anterior uveitic
patient with ankylosing spondylitis. )e mean central choroidal
thickness value is represented by a bold line.
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Figure 8: Swept-source OCT cross-sectional images of a 35-year-
old male anterior uveitic patient with seronegative spondy-
loarthropathy: (a) at the beginning of the anterior uveitis (0 days,
central retinal thickness: 234 µm, central choroidal thickness:
298 µm); (b) after 10 days in the treatment period (10 days, central
retinal thickness: 248 µm, central choroidal thickness: 267 µm); (c)
after a month (30 days, central retinal thickness: 219 µm, central
choroidal thickness: 242 µm).
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)is study also showed a significant decrease in cho-
roidal thickness in the eyes with active anterior uveitis
following anti-inflammatory treatment. It is widely known
that the choroid is influenced by ocular inflammatory
conditions. Several authors have suggested increased vas-
cular permeability in the posterior segment and choroidal
effusion as the mechanisms of choroidal thickening during
ocular inflammation [15, 16]. In the present study, the mean
values of subfoveal choroidal thickness in the eyes with AAU
changed significantly from 278.166 to 239.222 µm. )is
study showed a significant decrease in choroidal thickness in
the eyes with active anterior uveitis after treatment.
Our results indicate that subclinical choroidal in-
flammation may also be present in active anterior uveitis.
)ese findings suggest that choroidal evaluation may be
useful for monitoring disease activity.
Nevertheless, a larger case series could contribute to
a more sophisticated statistical evaluation of the patients
with AAU, but their common inflammatory pattern enables
us to study the inflammation effect of the retina and the
choroid.
In conclusion, swept-source OCT is also a useful tool in
monitoring subclinical retinal and choroidal thickening in
anterior uveitis with the SpA patients in the treatment
period. It may indicate that the retina and choroid play
a biomarker function in anterior segment inflammation but
the reply of the retina for the inflammatory agents seems to
be delayed.
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